secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edgewise Therapeutics, Inc. (EWTX)
CIK:        0001710072
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001104659-26-056783
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edgewise Q1 net loss $49M, cash $499.6M; sevasemten Becker data up to 3.5 years
-------------------------------------------------------------------------------

- Net loss $49.0M ($0.46/share) in Q1 2026 vs $40.8M ($0.43/share) in Q1 2025; cash and equivalents $499.6M.
- R&D expense $42.7M (up 16% YoY) driven by EDG-7500 and EDG-15400 clinical activity, partly offset by lower sevasemten costs.
- Long-term MESA OLE data shows sevasemten stabilizes function in Becker up to 3.5 years; 99% enrollment from prior trials.
- Pivotal GRAND CANYON sevasemten top-line results expected Q4 2026; marketing application planned H1 2027.
- CIRRUS-HCM Part D (EDG-7500) 12-week data in HCM expected Q2 2026; Phase 3 initiation H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926056783/0001104659-26-056783-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710072/000110465926056783/tm2613489d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-056783

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer